December 12, 2012 Leave a comment
I am happy to announce the publication of our initial observations regarding the important issues of Nagalase activity in ASD. The lab test itself only cost $65 from Health Diagnostics/ELN. Unfortunately it is generally not covered by most insurers in the US, but it is a worthwhile examination in my estimate.
This work represents the first clinical report of Nagalase activity in an autistic population. The article presents the first 40 children evaluated from 2 years ago. Since then and in collaboration with Dr Antonucci in Italy, we have observed over 1400 clinical cases. We will be collating our combined experiences and presenting-publishing a much larger series in the near future. Simply stated, both Dr Antonucci and I believe Nagalase and GcMAF therapy represent breakthroughs in autism-related comorbidities and therapies. We do caution parents enthusiastic to try this intervention to seek appropriate and experienced medical supervision. I am aware of numerous physicians in the US and around the World using this intervention.
Please Note: Neither the lab test, nor GcMAF are approved for diagnosing or treating any condition despite a substantial body of research in peer-reviewed journals over the past 2 decades.
You can read and download the entire article from the Libertas Academia website through the following link. If the link doesn’t work in your browser just copy and paste it into your browser.
Initial Observations of Elevated Alpha-N-Acetylgalactosaminidase Activity Associated with Autism and Observed Reductions from GC Protein—Macrophage Activating Factor Injections
Authors: James Jeffrey Bradstreet, Emar Vogelaar and Lynda Thyer
Publication Date: 10 Dec 2012
Citation: Autism Insights 2012:4 31-38
Background: Autism spectrum disorders (ASD) are developmental disorders affecting 1:88 children, and which appear to be associated with a variety of complex immune dysregulations including autoimmunity. The enzyme, alpha-N-acetylgalactosaminidase (Nagalase) deglycosylates serum Gc protein (vitamin D3 – binding protein) rendering it incapable of activating macrophage defenses. Increased Nagalase activity has been associated with a variety of malignancies, immune disorders and viral infections. Macrophage activating factor (GcMAF) has been repeatedly published as an intervention to lower serum Nagalase activity for a variety of cancer and HIV patients. GcMAF is a naturally occurring protein with well-established safety and therapeutic benefit(s) supported by numerous human studies.
Methods: Initially, parents of 40 individuals with ASD sought testing for Nagalase serum activity as part of an evaluation of immune dysregulation. Nagalase enzyme activity measurement was performed by the European Laboratory of Nutrients (ELN), Bunnik, the Netherlands, using an end-point enzymatic assay of a chromogenic substrate. Some parents of patients with elevated Nagalase activity opted for weekly GcMAF injections provided by Immuno Biotech Ltd., Guernsey UK (www.gcmaf.eu). GcMAF is purified from human serum obtained from the American Red Cross using 25-hydroxyvitamin D3-Sepharose high affinity chromatography. The protein is then further diluted to obtain therapeutically appropriate levels for patients based on their clinical presentations.
Results: Individuals with ASD (32 males and 8 females, n = 40, ages: 1 year 4 months – 21 years 2 months) had initial and post treatment assessment of Nagalase activity. Dosing of GcMAF was recommended based on previously reported response curves adjusted by the treating clinician for age, weight, and Nagalase levels. The average pre-treatment Nagalase activity of the autism group was 1.93 nmol/min/mg of substrate. This was well above the laboratory reported normal range of <0.95 nmol/min/mg. For the ASD group the average level at the time of second testing was 1.03 nmol/min/mg, reflecting an average reduction of 0.90 nmol/min/mg (P < 0.0001). Apart from the likely immunological benefits of lowering the Nagalase activity of these individuals, uncontrolled observations of GcMAF therapy indicated substantial improvements in language, socialization and cognition. No significant side-effects were reported during the course of injections.
Conclusions: In this first report of Nagalase activity in patients with autism, it appears that most individuals have substantially higher levels than the expected healthy ranges. Although Nagalase is a nonspecific marker of immune dysregulation, its observed levels in autism may have both etiological and therapeutic significance. Importantly, this is also the first report of reduction of Nagalase activity in an autism population with GcMAF injections.